Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 682
Rating:

Prof Sandip Patel - UC San Diego, San Diego, USA

Prof Sandip Patel speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the DART study, which examined the administration of ipilimumab plus nivolumab to achieve dual checkpoint inhibition in a cohort of patients with rare neuroendocrine tumours.

Prof Patel reports that these patients experienced a 44 percent reduction in tumour size, compared with patients with lower, intermediate disease - who experienced a 0 percent rate of shrinkage.

Although it is unclear why patients with high-grade neuroendocrine carcinoma benefitted from this study, Prof Patel points out that it may be attributed to a mutational burden; in which specimens are being assessed to understand the underlying tumour biology.

He also believes in the next three years, oncologists will be able to determine which rare tumour types display a sensitivity to immune checkpoint blockade - which may include high-grade neuroendocrine carcinoma.

Read more about this research here.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation